Multiple favorable factors drive the sector's vitality, and the innovative drug industry enters a commercialization harvest period

Zhitong
2025.05.05 22:37

Recently, the Chinese innovative drug industry has been receiving continuous positive news, and the industry's prosperity has improved. The highly anticipated American Association for Cancer Research annual meeting was held in Chicago, where several Chinese innovative drug companies were invited to attend. At the same time, companies such as INNOVENT BIO and KANGFANG BIO have made phased breakthroughs with their related products; some innovative drug companies have reported impressive first-quarter and annual report data, achieving significant year-on-year growth. Industry insiders believe that with policy support, increased market recognition, improved investment and financing environment, and the gradual emergence of research and development results, the innovative drug sector has a broad development prospect. Benefiting from multiple positive factors, the pharmaceutical industry is expected to continue to see valuation recovery in 2025

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer